It looks like we have a new generation of PSMA directed antibody-drug conjugates ready for clinical trials!
SDV2102, a novel antibody-drug conjugate for metastatic castration-resistant prostate cancer, targets PSMA with a unique low drug-to-antibody ratio, enhancing tumor penetration and safety. Using the D10 antibody and MMAE, it showed superior tumor reduction in mouse models with high and low PSMA expression, outperforming traditional ADCs. SDV2102 also demonstrated no major toxicity in primates at high doses. Its versatility across PSMA levels and favorable safety profile make it a promising candidate for clinical trials, potentially offering new hope for mCRPC patients.
New strategies against bone metastases from prostate cancer - Science Daily
